Antibiotics-an investment worth making?

Article Abstract:

Demand for new and more effective antibiotics is growing continuously and handsome returns on successful antibiotic drugs make them an interesting option for biotech investment by venture capitalist. However, the dangers from new regulatory, political, scientific and clinical trends are making venture capitalist cautious and they putting serious thought before entering into investments.

United States, Market information - general, Financial management, Biotechnology industry, Biotechnology industries, Company investment, Investments, Supply and demand, Antibiotics

---

Genetech faces the consequences of growth

Article Abstract:

The biotech firm Genetech is unable to produce the pipeline that is necessary to increase its financial growth due to its large size. The failure of recognition as a pharma or even a biotech firm could be avoided by planning strategies for acquisitions and in-licensing.

Market share, Management dynamics, Management, Biological products industry, Genentech Inc., Company business management, Company market share, DNA

---

Similar abstracts:

• Abstracts: Asset sales, investment opportunities, and the use of proceeds. Optimal asset location and allocation with taxable and tax-deferred investing
• Abstracts: Investment and financing constraints: evidence from the funding of corporate pension plans. The foundations of freezeout laws in takeovers
• Abstracts: After price complaints, DOD works with Contractors on costs
• Abstracts: Financial factors in R&D budget setting: the impact of interfunctional market coordination, strategic alliances, and the nature of competition
• Abstracts: A passion for collaboration from the get-go: Merk and Co., Inc. and Bioxell show how big pharma and small biotechs can make perfect partners

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.